Columbus, OHNCT05417165Now EnrollingIRB Ready

Chronic Lymphocytic Leukemia Clinical Trial in Columbus, OH

Access cutting-edge chronic lymphocytic leukemia treatment through this phase 2 clinical trial at a research site in Columbus. Study-provided care at no cost to qualified participants.

Sponsored by Seema Bhat

Quick Self-Assessment

See if you qualify for this Columbus location

Preparing your pre-screening questions…

Expert Care in Columbus

Access chronic lymphocytic leukemia specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related chronic lymphocytic leukemia treatment provided free

Apply for This Columbus Location

Check if you qualify for this chronic lymphocytic leukemia clinical trial in Columbus, OH

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Columbus

    Convenient for OH residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Columbus site if eligible
  4. 4Begin participation

About This Chronic Lymphocytic Leukemia Study in Columbus

This phase II trial compares the effect of initial vaccination (PCV20 followed by PSV23) with yearly vaccinations of PSV23 to the standard 5 year vaccination in patients with chronic lymphocytic leukemia. At present chronic lymphocytic leukemia patients are poorly protected by anti-pneumococcal vaccination. Current vaccination schedule for chronic lymphocytic leukemia patients is based on general recommendations in immunocompromised patients (initial vaccination with PCV13 followed by one dose of PSV23 after an interval of two months, followed by revaccination at 5 years). Giving patients frequent immunization as compared to 5 year immunization may result in higher protective titers in patients.

Sponsor: Seema Bhat

Who Can Participate

Inclusion Criteria

Men and women \>= 18 years of age
Patients must have histologically identified chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) as defined by the World Health Organization (WHO) classification of hematopoietic neoplasms
Treatment naive CLL/SLL; No prior therapy for CLL/SLL, including chemotherapy and/or radiotherapy is allowed
Estimated life expectancy of greater than 24 months

Exclusion Criteria

Patients with neutropenic (granulocyte \[PMN\]s \< 500 cells/mm\^3) or having received rituximab within 6 months
Patients with fever (temperature \> 38 degrees Celsius \[C\]) within 1 week
Active infection, recent infection requiring systemic treatment that was completed =\< 14 days before starting treatment on the study
Patients with known human immunodeficiency virus (HIV) infection
History of allergic reactions attributable to compounds of similar chemical or biologic composition to any component of pneumococcal vaccines
Chemotherapy in 4 weeks or received Rituximab or similar anti CD20 monoclonal antibody for non-hematological indications within 6 months
Received intravenous immunoglobulin (IVIG) within 3 months prior to vaccination
History of allogenic stem cell transplantation
Patients who have received cellular therapy (e.g. CAR-T cells) within 12 months prior to vaccination
Patients who have previously received pneumococcal vaccine within the preceding 12 months
Absolute lymphocyte count less than 500 cells/mm\^3
Patient with other severe immune deficiency
Patients may not be receiving any other investigational agents
Active malignancy from which the subject is considered by his or her physician to have a less than 24 month survival expectation. Non-melanoma skin cancer is not an exclusion criterion.
Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection and/or psychiatric illness/social situations that would limit compliance with study requirements
Concurrent systemic immunosuppressant therapy (e.g., cyclosporine A, tacrolimus, etc., or chronic administration \[\> 14 days\] of \> 20 mg/day of prednisone) within 14 days of the first dose of study drug
Because of the potential for H2-blockers to modulate antibody response to pneumococcal vaccine, patients must discontinue treatment with H2-blockers (cimetidine, ranitidine, etc.) prior to beginning protocol therapy
Unwilling or unable to participate in all required study evaluations and procedures
Unable to understand the purpose and risks of the study and to provide a signed and dated informed consent form (ICF) and authorization to use protected health information (in accordance with national and local subject privacy regulations)

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Columbus?

Yes, this clinical trial (NCT05417165) has an active research site in Columbus, OH that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Chronic Lymphocytic Leukemia Treatment Options in Columbus, OH

If you're searching for chronic lymphocytic leukemia treatment options in Columbus, OH, this clinical trial (NCT05417165) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Columbus research site is actively enrolling participants for this phase 2 clinical trial. You'll receive care from experienced chronic lymphocytic leukemia specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all chronic lymphocytic leukemia clinical trials near you to find additional studies recruiting in your area.

More Leukemia Trials in Columbus, OH

See all leukemia clinical trials recruiting in Columbus — not just this study.

Browse Leukemia Trials in Columbus →

Browse More Trials by Condition

Leukemia TrialsChronic Lymphocytic Leukemia TrialsHeart Attack TrialsPulmonary Hypertension TrialsInterstitial Cystitis TrialsMyocardial Infarction TrialsAll Conditions →

Ready to Join in Columbus?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Columbus, OH